What smart money is saying about Pfizer
PFE
No fund has written a full thesis on Pfizer in our archive, but 1 fund letter reports a position in it — most recently FPA Queens Road Value Fund in June 2026.
Get an email when a fund writes about it
1
Reported positions
0
Bought
0
Sold
2
Letters
Position history
Every position in Pfizer on record in the archive was reported in Q2 2026, across 1 fund letter, with no move described.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2026 | 1 | 0 | 0 | 0 |
Fund activity · 1 position
- June 2026
“Our top detractors for the quarter were Hershey, Pfizer, McDonald’s, RTX and Allegion.”
Pfizer
Also mentioned · 1
These funds discuss Pfizer — as a competitor, benchmark or comparable — without disclosing a position in it.
- June 2026
“Biologics have been coming into vogue over the last couple of decades, and so many of McKesson’s largest opportunities are in this category. As the name implies, biologics are derived from living organisms rather than static formulas of chemicals. These typically require more delicate storage and handling, for example, Pfizer states their COVID-19 vaccine is required to be stored between -90°C and -60°C.”
Pfizer
Read the letters behind these Pfizer positions
Every quote above comes from a fund letter in our archive. Get unlimited access to the letters themselves — and to Warren AI, which reads all of them for you.
View plans→Share this ledger